262 related articles for article (PubMed ID: 31056722)
1. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
[TBL] [Abstract][Full Text] [Related]
2. Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma.
Jaracz J; Kucharska A; Rajewska-Rager A; Lacka K
J Endocrinol Invest; 2012 Sep; 35(8):760-5. PubMed ID: 21986400
[TBL] [Abstract][Full Text] [Related]
3. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma.
Moon JH; Ahn S; Seo J; Han JW; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Kim KW; Jang HC
J Clin Endocrinol Metab; 2014 Oct; 99(10):3782-9. PubMed ID: 25029415
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Stimulating Hormone Suppression in the Long-term Follow-up of Differentiated Thyroid Cancer.
Freudenthal B; Williams GR
Clin Oncol (R Coll Radiol); 2017 May; 29(5):325-328. PubMed ID: 28043744
[TBL] [Abstract][Full Text] [Related]
5. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
6. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.
Altuntaş SÇ; Hocaoğlu Ç
Horm Metab Res; 2021 Oct; 53(10):683-691. PubMed ID: 34607367
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
Zhang Q; Zhong ZZ; Wu T; He YQ
BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
[TBL] [Abstract][Full Text] [Related]
9. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
Sugitani I; Fujimoto Y
Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
[TBL] [Abstract][Full Text] [Related]
10. Prediction of thyroid hormone supplementation after thyroid lobectomy.
Lee DY; Seok J; Jeong WJ; Ahn SH
J Surg Res; 2015 Jan; 193(1):273-8. PubMed ID: 25088372
[TBL] [Abstract][Full Text] [Related]
11. Glucose tolerance and lipid profile in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trial.
Heemstra KA; Smit JW; Eustatia-Rutten CF; Heijboer AC; Frölich M; Romijn JA; Corssmit EP
Clin Endocrinol (Oxf); 2006 Dec; 65(6):737-44. PubMed ID: 17121524
[TBL] [Abstract][Full Text] [Related]
12. Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.
Fussey JM; Khan H; Ahsan F; Prashant R; Pettit L
Head Neck; 2017 Dec; 39(12):2567-2572. PubMed ID: 28960722
[TBL] [Abstract][Full Text] [Related]
13. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
[TBL] [Abstract][Full Text] [Related]
14. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
15. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
16. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.
Santoro AB; Vargens DD; Barros Filho Mde C; Bulzico DA; Kowalski LP; Meirelles RM; Paula DP; Neves RR; Pessoa CN; Struchine CJ; Suarez-Kurtz G
Br J Clin Pharmacol; 2014 Nov; 78(5):1067-75. PubMed ID: 24910925
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of reliable pituitary suppression therapy through varying thyroid hormone dosage following total thyroidectomy due to a differentiated thyroid carcinoma].
Wahl R; Hüfner M; Röher HD; Papke W
Langenbecks Arch Chir; 1975; Suppl():469-74. PubMed ID: 1207280
[TBL] [Abstract][Full Text] [Related]
18. Cognitive dysfunction associated with activation of the mTOR signaling pathway after TSH suppression therapy in rats.
Liu Y; Jin S; Yang YT; Bai Y; Yong H; Bao W
Endocr J; 2020 Oct; 67(10):1063-1070. PubMed ID: 32581146
[TBL] [Abstract][Full Text] [Related]
19. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial.
Eustatia-Rutten CF; Corssmit EP; Pereira AM; Frölich M; Bax JJ; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Mar; 64(3):284-91. PubMed ID: 16487438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
